ARTICLE INFO

Article history
Received: 3 August 2021
Accepted: 9 August 2021
Published Online: 20 August 2021

Keywords:
Non-small cell lung cancer
Radiotherapy
Postoperative
Prognosis

ABSTRACT

The purpose of this study is to clarify the significance of postoperative radiotherapy for N2 lung cancer. This study aimed to investigate the effect of postoperative radiotherapy on the survival and prognosis of patients with N2 lung cancer. Data from 12,000 patients with N2 lung cancer were extracted from the Surveillance, Epidemiology, and End Results database (2004-2012). Age at disease onset and 5-year survival rates were calculated. Survival curves were plotted using the Kaplan-Meier method. The univariate log-rank test was performed. Multivariate Cox regression were used to examine factors affecting survival. Patients’ median age was 67 years (mean 66.46 ± 10.03). The 5-year survival rate was 12.55%. Univariate analysis revealed age, sex, pathology, and treatment regimen as factors affecting prognosis. In multivariate analysis, when compared to postoperative chemotherapy, postoperative chemoradiotherapy was better associated with survival benefits (hazard ratio [HR]= 0.85, 95% confidence interval [CI]: 0.813-0.898, \( P < 0.001 \)). Propensity score matching revealed that patients who had received postoperative chemoradiotherapy had a better prognosis than did patients who had received postoperative chemotherapy (HR=0.869, 95% CI: 0.817-0.925, \( P < 0.001 \)). Female patients and patients aged <65 years had a better prognosis than did their counterparts. Patients with adenocarcinoma had a better prognosis than did patients with squamous cell carcinoma. Moreover, prognosis worsened with increasing disease T stage. Patients who had received postoperative chemoradiotherapy had a better prognosis than did patients who had received postoperative chemotherapy. Postoperative radiotherapy was an independent prognostic factor in this patient group.
1. Introduction

Lung cancer is a common cancer type and the leading cause of cancer-related deaths worldwide \[1\]. In 2018, there were 2.1 million new lung cancer cases and 1.8 million lung cancer-related deaths, accounting for 18.4% of all cancer-related deaths \[2\]. Non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancer cases \[3\], among which adenocarcinoma and squamous cell carcinoma are the predominant types. Surgery is the standard treatment for NSCLC. Currently there are no guidelines on adjuvant treatment for patients with postoperative pathological N2 disease stage. Adjuvant chemotherapy is the standard treatment for patients with positive lymph node metastasis after operation, but there was a significant difference in whether adjuvant radiotherapy was performed.

2. Methods

The Surveillance, Epidemiology, and End Results (SEER) database was examined for data from lung cancer patients with a pathological diagnosis of NSCLC confirmed during 2004-2012. (Figure 1). Patients were included in the present study if they met the following criteria: (1) Their postoperative stage was N2M0; (2) Squamous cell carcinoma or adenocarcinoma was confirmed by pathology testing; (3) Postoperative treatment involved chemotherapy alone; (4) Diagnosis was confirmed during 2004-2012.

Patients were excluded from the present study if they met any of the following criteria: (1) Unclear pathology results or confirmed diagnosis of a cancer type other than squamous cell carcinoma or adenocarcinoma; (2) Confirmed metastasis; (3) Intraoperative or preoperative treatment with radiotherapy; (4) No postoperative chemotherapy; (5) Confirmed multiple primary tumors; (6) Incomplete data.

![Figure 1. schematic illustration](https://example.com/figure1.png)

**Statistical analysis**

IBM SPSS statistics version 25 was used for statistical analysis. Chi-square test was used to analyze categorical variables. Survival curves were plotted using the Kaplan-Meier method, and log-rank test was performed to analyze the differences in variables among groups. Differential variables were subjected to propensity score matching (PSM) in the postoperative chemoradiotherapy and postoperative chemotherapy group, and differences among groups were examined after matching. Univariate analysis was applied to compute models that included sex, stage, pathology, age, and treatment regimen. The variables that were significant in univariate analysis were included in multivariate analysis. Cox proportional hazards model was used for multivariate analysis. P-values <0.05 were considered statistically significant.

3. Results

**Descriptive statistics**

Among the 12,000 included patients. The age range was 19-95 years, with a median of 67 years (mean 66.46 ± 10.03 years). There 6127 cases (51.06%) were T0-2, 5873 cases (48.94%) were T3-4 (Table 1).

### Table 1. Demographic and clinical characteristics of patients with squamous cell carcinoma and adenocarcinoma included in the Surveillance, Epidemiology, and End Results (SEER) database

| Group                        | Cases | Percentage (%) |
|------------------------------|-------|----------------|
| **Sex**                      |       |                |
| Male                         | 7119  | 59.33          |
| Female                       | 4881  | 40.67          |
| **Stage**                    |       |                |
| T0                           | 66    | 0.55           |
| T1                           | 1640  | 13.67          |
| T2                           | 4421  | 36.84          |
| T3                           | 1842  | 15.35          |
| T4                           | 4031  | 33.59          |
| **Pathology**                |       |                |
| Squamous cell carcinoma      | 6652  | 55.43          |
| Adenocarcinoma               | 5348  | 44.57          |
| **Age**                      |       |                |
| ≤ 65 years                   | 5344  | 44.53          |
| > 65 years                   | 6656  | 55.47          |
| **Treatment**                |       |                |
| Postoperative chemoradiotherapy | 2606  | 21.72          |
| Postoperative chemotherapy   | 9394  | 78.28          |

**Univariate analysis**

Kaplan-Meier curves were plotted according to sex,
stage, pathology, age, and treatment regimen, revealing differences between groups. Women had a better prognosis than did men; patients aged 65 years and younger had a better prognosis than did patients older than 65 years; patients with adenocarcinoma had a better prognosis than did patients with squamous cell carcinoma; however, the prognosis worsened with increasing T stage. The prognosis of patients who had received postoperative chemoradiation therapy was better than that of patients who had received postoperative chemotherapy. There were statistically significant differences in gender, stage, pathology, age and treatment plan between groups ($P < 0.01$) (Figure 2).

**Multivariate analyses**

Multivariate analyses are carried out on the variables with significance of univariate analysis. Gender, T stage, pathology, age and treatment were included in the multivariate analysis. T stage was divided into T0-2 group and T3-4 group, as shown in Table 2.

| Group     | Univariate analysis | Multivariate analysis |
|-----------|---------------------|-----------------------|
|           | $P$  | OR    | 95% CI | $P$  | HR    | 95% CI |
| Sex       | < 0.001 | 1.434 | 1.236-1.663 | < 0.001 | 1.131 | 1.085-1.178 |
| Stage     | < 0.001 | 0.722 | 0.654-0.796 | < 0.001 | 0.820 | 0.788-0.854 |
| Pathology | < 0.001 | 1.348 | 1.158-1.569 | < 0.001 | 1.142 | 1.085-1.178 |
| Age       | < 0.001 | 0.808 | 0.697-0.933 | < 0.001 | 0.887 | 0.852-0.923 |
| Treatment | < 0.001 | 0.807 | 0.697-0.934 | < 0.001 | 0.855 | 0.813-0.898 |

HR=hazard ratio

**Figure 2.** Kaplan-Meier curves of overall survival according to different groups. Survival difference of patients in group was statistically significant ($p<0.001$).
Propensity score matching

After matching on sex, stage, pathology findings, and age, a total of 4,842 patients were included and divided evenly between the postoperative chemoradiotherapy (n=2421) and postoperative chemotherapy group (n = 2421). The sample included 2,779 men and 2,063 women. There were 21 cases at T0 stage, 1,091 cases at T1 stage, 1,922 cases at T2 stage, 556 cases at T3 stage, and 1,252 cases at T4 stage. There were 2,185 cases of squamous cell carcinoma and 2,657 cases of adenocarcinoma. There were 2,300 patients aged 65 years or younger and 2,542 patients older than 65 years. The age range was 19-90 years, with a median of 66 years (mean 65.66 ± 9.72). The 5-year survival rate and median survival time before and after matching are presented in Table 2. Before matching, the median survival time was 17 months, and the 5-year survival rate was 12.55%; after matching, the median survival time was 19 months, and the 5-year survival rate was 18.5%. The prognosis of patients who had received postoperative chemoradiotherapy was significantly better than that of patients who had received postoperative chemotherapy alone (hazard ratio [HR]=0.869, 95% confidence interval [CI]: 0.817-0.925, P <0.001).

Treatment regimen was an independent prognostic factor for lung cancer patients (Table 3, and Figure 3 and 4).

Table 3. Survival outcomes for lung cancer patients included in the Surveillance, Epidemiology, and End Results (SEER) database, before and after propensity score matching

| Group                      | Before matching |                           | After matching |                           |
|----------------------------|-----------------|---------------------------|----------------|---------------------------|
|                            | Cases           | Percentage (%)            | 5-year survival rate (%) | Median survival time (months) | Cases           | Percentage (%)            | 5-year survival rate (%) | Median survival time (months) |
| Sex                        |                 |                           |                 |                           |                 |                           |                 |                           |
| Male                       | 7119            | 59.33                     | 11.14           | 16                        | 2779            | 57.39                     | 15.87           | 17                        |
| Female                     | 4881            | 40.67                     | 14.61           | 18                        | 2063            | 42.61                     | 22.06           | 22                        |
| Stage                      |                 |                           |                 |                           |                 |                           |                 |                           |
| T0                         | 66              | 0.55                      | 30.30           | 37                        | 21              | 0.43                      | 38.10           | 28                        |
| T1                         | 1640            | 13.67                     | 19.02           | 23                        | 1091            | 22.53                     | 24.01           | 24                        |
| T2                         | 4421            | 36.84                     | 12.12           | 18                        | 1922            | 39.69                     | 18.21           | 20                        |
| T3                         | 1842            | 15.35                     | 12.87           | 16                        | 556             | 11.48                     | 16.19           | 11                        |
| T4                         | 4031            | 33.59                     | 9.95            | 14                        | 1252            | 25.88                     | 14.86           | 15                        |
| Pathology                  |                 |                           |                 |                           |                 |                           |                 |                           |
| Squamous cell carcinoma    | 6652            | 55.43                     | 10.34           | 15                        | 2185            | 45.13                     | 15.56           | 16                        |
| Adenocarcinoma             | 5348            | 44.57                     | 15.30           | 19                        | 2657            | 54.87                     | 20.93           | 21                        |
| Age                        |                 |                           |                 |                           |                 |                           |                 |                           |
| ≤ 65 years                 | 5344            | 44.53                     | 14.20           | 17                        | 2300            | 47.50                     | 20.04           | 20                        |
| > 65 years                 | 6656            | 55.47                     | 11.22           | 16                        | 2542            | 52.51                     | 17.11           | 18                        |
| Treatment                  |                 |                           |                 |                           |                 |                           |                 |                           |
| Postoperative chemotherapy + radiotherapy | 2606 | 21.72                     | 16.58           | 21                        | 2421            | 50                         | 20.12           | 21                        |
| Postoperative chemotherapy  | 9394            | 78.28                     | 11.43           | 16                        | 2421            | 50                         | 16.89           | 17                        |

Figure 3. Survival curve at mean of covariates

Figure 4. Significant difference survival curve of between after-matching PORT and NO-PORT (p<0.001).
4. Discussion

NSCLC is a common type of lung cancer, of which adenocarcinoma and squamous cell carcinoma are the predominant subtypes. At the time of diagnosis, 30%-40% of patients have been reported to have disease at a locally advanced stage, accompanied by metastasis of cancer cells. However, controversy surrounds administration of adjuvant radiotherapy. Based on data from the National Cancer Database (NCDB), Drake et al. have reported no difference in the median survival time between patients treated with adjuvant chemoradiotherapy and patients treated with adjuvant chemotherapy after R0 resection of disease at stage N0 and pathological N2 (3.9 years vs 3.8 years, \( P = 0.705 \)) [14]. Moreover, Spicer et al. have conducted a retrospective analysis of data from four chest tumor centers, and compared 5-year overall survival (OS) and disease-free survival (DFS) in patients treated with N2 postoperative chemotherapy and N2 postoperative concurrent chemoradiotherapy. Their study revealed no differences in recurrence rates, recurrence mode, perioperative mortality, OS, or DFS in patients who had received preoperative invasive mediastinal staging [15].

It has been reported that postoperative radiotherapy can benefit pN2 patients. The American Thoracic Society guidelines did not support administration of adjuvant radiotherapy for occult N2 (NSCLC) after RO resection. Postoperative radiotherapy increased the local control rate but did not improve the OS rate [16]. A meta-analysis of relevant studies has shown that adjuvant radiotherapy lacked survival benefits after complete resection of NSCLC compared with operation alone. In 2006, Lally et al., using the SEER data, argued that postoperative radiotherapy improved the survival rate of N2 patients but did not benefit patients with disease stage N0 or N1 [17]. Douillard et al. have retrospectively analyzed data from pN2 patients who had received postoperative adjuvant radiotherapy, revealing that postoperative adjuvant radiotherapy generated more benefits but showed a negative effect on pN1 [18]. Based on data from the National Cancer Database, Hershkovic et al. have conducted a stratified analysis to examine whether 2,691 patients with negative N2 (II) A resection margin who had received adjuvant chemotherapy during 2004-2013 should receive postoperative radiotherapy. In their study, the median survival time was 27.43 months and 25.86 months (\( p < 0.05 \)), respectively. Postoperative radiotherapy significantly prolonged survival [19]. With improvements to radiotherapy technology, the local control rate increased, and treatment toxicity decreased [20]. Moreover, Su et al. have found that 1-year, 3-year, and 5-year OS rates associated with postoperative chemoradiotherapy and postoperative chemotherapy were 98.3% vs 86.1%, 71.7% vs 53.0% and 45.7% vs 39.0%, respectively (\( P = 0.019 \)) [21].

In summary, there have been many studies aimed at examining the efficacy of N2 postoperative treatment regimens. In the present study, which involved analysis of data from the SEER database, we have shown that age, sex, disease stage, pathology type, and treatment regimen are factors that affect the prognosis of patients with N2 lung cancer. In the present study, women and patients with adenocarcinoma had a better prognosis than did men and patients with squamous cell carcinoma. These findings suggest that targeted therapy can be considered to prolong survival. Multivariate analysis has revealed that survival associated with postoperative chemoradiotherapy was longer than survival time associated with postoperative chemotherapy alone. With the development of novel immunotherapy and targeted therapy regimens, further research is needed to identify the optimal postoperative treatment regimen for N2 lung cancer.
5. Conclusions

It can be seen from this study that the prognosis of N2 lung cancer is affected by many factors. Young, female and adenocarcinoma patients have more survival advantages. With the increase of T stage, the prognosis is worse and worse. Postoperative adjuvant radiotherapy is better than postoperative chemotherapy alone.

Acknowledgements

We would like to thank Editage (www.editage.cn) for English language editing.

Statement of Interest

There is no conflict of economic interests affecting its scientificity and credibility in this study.

Funding

Project of Hebei Medical Science Research Plan in 2021 (20210831).
National key research and development program of China (2018YFE0114100).

References

[1] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global Cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.
[2] Freddie Bray, BSc, MSc, Jacques Ferlay, ME, Isabelle Soerjomataram. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA cancer J clin 2018;68:394-424.
[3] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017.CA:Cancer J Clin.2017;67:7-30.
[4] Lam P, AuYeung KM, Cheng PW, et al. Correlating MRI and histologic tumor thickness in the assessment of oral tongue cancer. J. AJR Am J Roentgenol, 2004, 182(3):803-808.
[5] Hiroaki Tsunezuka, Hiroaki Tsunezuka, Treatment rationale and design of the induction chemotherapy and adjuvant thoracic radiation in resectable N2-3A/3B non-small cell lung cancer (ICAT) study. J. Medicine.2019 Jul;98(27):e16298.
[6] Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-8.
[7] NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 2014;383:1561-71.
[8] Farray D, Mirkovic N, Albain KS. Multimodality therapy for stage III non- small- cell lung cancer. J Clin Oncol. 2005;23(14):3257-3269.
[9] Willers H, Stinchcombe TE, Barriger RB, et al. ACR Appropriateness Criteria(R) induction and adjuvant therapy for N2 nonsmall-cell lung cancer. Am J Clin Oncol 2015; 38:197-205.
[10] Iwai H, Kyomoto R, HaKawa SK, et al. Magnetic resonance determination of tumor thickness as predictive factor of cervical metastasis in oral tongue carcinoma. J. Laryngoscope, 2002,112(3):457-461.
[11] NSCLC Meta-analyses Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 2014; 383:1561-1571.
[12] Arriagada R, Auperin A, Burdett S, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010; 375:1267-1277.
[13] Robinson CG, Patel AP, Bradley JD, DeWees T, Waqar SN, Morgensztern D, Baggsom MQ, Govindan R, Bell JM, Guthrie TJ. Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: A review of the National Cancer Data Base. J Clin Oncol. 2015;33:870.
[14] Justin A. Drake, MD, David C. Portnoy, MD, Kurt Tauer, MD, et al. Adding Radiotherapy to Adjuvant Chemotherapy Does Not Improve Survival of Patients With N2 Lung Cancer. J. Ann Thorac Surg 2018;106:959-65.
[15] Jonathan D. Spicer, Jitesh B. Shewale, BDS, David B. Nelson, et al. Multimodality Therapy for N2 Non-Small Cell Lung Cancer: An Evolving Paradigm. J. Ann Thorac Surg 2019;107:277-84.
[16] Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physiciansevidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e314S-40S.
[17] Brian E. Lally, Daniel Zelterman, Joseph M. Colasanto, et al. Postoperative Radiotherapy for Stage II or III Non-Small-Cell Lung Cancer Using the Surveillance, Epidemiology, and End Results Database. J. Journal of clinical oncology. 2006. 19, 24, 2998-3006.
[18] Jean-Yves Douillard , Rafael Rosell, Mario De Lena,
et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage i, ii, or iiia non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant navelbine international trialist association (anita) randomized trial. Int. J. Radiation Oncology Biol. Phys., 2008. 72, 3, 695-701.

[19] Alex Herskovic, Elizabeth Mauer, Paul Christos, Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non-Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database. J. Thorac Oncol. 2017 Feb;12(2):302-313.

[20] Rosenzweig K. Stereotactic Body Radiation Therapy as an Alternative to Surgery in Early-Stage Non-Small-Cell Lung Cancer. Oncology (Williston Park)2017;31:492-8.

[21] Liyu Su, Mingqiu Chen, Huiyan Su, et al. Postoperative chemoradiotherapy is superior to postoperative chemotherapy alone in squamous cell lung cancer patients with limited N2 lymph node metastasis. J.BMC Cancer (2019) 19:1023.